Primary and secondary disorders of lipid metabolism in pediatrics

Pediatric Endocrinology Reviews

Volumn 5, Issue SUPPL. 2, 2008, Pages 727-738

  Kwiterovich, Peter O ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Dyslipidemia; Lipoproteins; Pediatric

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN; ATORVASTATIN; BILE ACID SEQUESTRANT; CHOLESTEROL; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; ESTROGEN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MEVINOLIN; NICOTINIC ACID; PHOSPHOLIPID; PRAVASTATIN; PROGESTERONE; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIET THERAPY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; GASTROINTESTINAL SYMPTOM; HUMAN; LIFESTYLE MODIFICATION; LIPID METABOLISM; MEDICAL SOCIETY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRACTICE GUIDELINE; REVIEW; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHILD; DIABETES MELLITUS, TYPE 1; DIET; FEMALE; HUMANS; LIFE STYLE; LIPID METABOLISM DISORDERS; LIPOPROTEINS; MALE; METABOLIC SYNDROME X; NEPHROTIC SYNDROME; PEDIATRICS; POLYCYSTIC OVARY SYNDROME;

EID: 41549151164     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421
2. American Association of Clinical Endocrinologists (AACE) Lipid Guidelines Committee. The American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of dyslipidemia and prevention of atherogenesis: 2002 amended version (online). Accessed April 30, 2007
3. Kavey RE, Allada V, Daniels SR, Hayman LL, McCrindle BW, Newburger JW, Parekh RS, Steinberger J. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2006;114:2710-2738
4. Tuzcu EM, Kapadia SR, Tutar E, Ziada KM, Hobbs RE, McCarthy PM, Young JB, Nissen SE. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 2001;103:2705-2710
5. NCEP Expert Panel on Blood Cholesterol Levels in Children and Adolescents. National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992;89:495-501
6. Kingsbury KJ, Bondy G. Understanding the essentials of blood lipid metabolism. Prog Cardiovasc Nurs 2003;18:13-18
7. Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation 2004;109:III 2-III 7
8. Mahley RW. Heparan sulfate proteoglycan/low density lipoprotein receptor-related protein pathway involved in type III hyperlipoproteinemia and Alzheimer's disease. Isr J Med Sci 1996;32:414-429
9. Kwiterovich PO, Jr. The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. Am J Cardiol 2000;86:5L-10L
10. Fredenrich A, Bayer P. Reverse cholesterol transport, high density lipoproteins and HDL cholesterol: recent data. Diabetes Metab 2003;29:201-205
11. Ohashi R, Mu H, Wang X, Yao Q, Chen C. Reverse cholesterol transport and cholesterol efflux in atherosclerosis. QJM 2005;98:845-856
12. American Academy of Pediatrics. National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992;89:525-584
13. Bachorik PS, Lovejoy KL, Carroll MD, Johnson CL. Apolipoprotein B and Al distributions in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III). Clin Chem 1997;43:2364-2378
14. Dyslipidemia (hyperlipidemia). In: Porter RS, Kaplan JL, eds. The Merck Manual Online. Vol Online (based on 18th print edition). Whitehouse Station, NJ: Merck Research Laboratories; 2006-2007
15. Wang J, Cao H, Ban MR, Kennedy BA, Zhu S, Anand S, Yusuf S, Pollex RL, Hegele RA. Resequencing genomic DNA of patients with severe hypertriglyceridemia (MIM 144650). Arterioscler Thromb Vasc Biol 2007;27:2450-2455
16. McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, Hayman LL, Daniels SR. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007;115:1948-1967
17. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-809
18. Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 1998;82:57U-66U; discussion 86U
19. Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nat Med 2002;8:1235-1242
20. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation 1990;82:1138-1146
21. Berenson GS, Srinivasan SR, Bao W, Newman WP, 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998;338:1650-1656
22. Klag MJ, Ford DE, Mead U, He J, Whelton PK, Liang KY, Levine DM. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med 1993;328:313-318
23. American Heart Association. Youth and cardiovascular diseases: statistics 2007 update (online). Accessed April 30, 2007
24. Chen W, Srinivasan SR, Li S, Xu J, Berenson GS. Clustering of long-term trends in metabolic syndrome variables from childhood to adulthood in Blacks and Whites: the Bogalusa Heart Study. Am J Epidemiol 2007;166:527-533
25. Silverstein J, Klingensmith G, Copeland K, Plotnick L, Kaufman F, Laffel L, Deeb L, Grey M, Anderson B, Holzmeister LA, Clark N. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care 2005;28:186-212
26. Teng B, Thompson GR, Sniderman AD, Forte TM, Krauss RM, Kwiterovich PO, Jr. Composition and distribution of low density lipoprotein fractions in hyperapobetalipoproteinemia, normolipidemia, and familial hypercholesterolemia. Proc Natl Acad Sci USA 1983;80:6662-6666
27. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996;276:875-881
28. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276:882-888
29. Holmes KW, Kwiterovich PO, Jr. Treatment of dyslipidemia in children and adolescents. Curr Cardiol Rep 2005;7:445-456
30. de Ferranti SD, Gauvreau K, Ludwig DS, Neufeld EJ, Newburger JW, Rifai N. Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. Circulation 2004;110:2494-2497
31. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K, Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004;350:2362-2374
32. Vos LE, Oren A, Uiterwaal C, Gorissen WH, Grobbee DE, Bots ML. Adolescent blood pressure and blood pressure tracking into young adulthood are related to subclinical atherosclerosis: the Atherosclerosis Risk in Young Adults (ARYA) study. Am J Hypertens 2003;16:549-555
33. Janssen I, Katzmarzyk PT, Srinivasan SR, Chen W, Malina RM, Bouchard C, Berenson GS. Utility of childhood BMI in the prediction of adulthood disease: comparison of national and international references. Obes Res 2005;13:1106-1115
34. Ranbaxy Laboratories Inc. Riomet (metformin hydrochloride oral solution) (package insert). Jacksonville, FL; 2005
35. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001;107:E55
36. Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001;50:1457-1461
37. Vryonidou A, Papatheodorou A, Tavridou A, Terzi T, Loi V, Vatalas IA, Batakis N, Phenekos C, Dionyssiou-Asteriou A. Association of hyperandrogenemic and metabolic phenotype with carotid intimamedia thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:2740-2746
38. Bridger T, MacDonald S, Baltzer F, Rodd C. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med 2006;160:241-246
39. Glueck CJ, Aregawi D, Winiarska M, Agloria M, Luo G, Sieve L, Wang P. Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. J Pediatr Endocrinol Metab 2006;19:831-842
40. Prescott WA, Jr., Streetman DA, Streetman DS. The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome. Ann Pharmacother 2004;38:2105-2114
41. Crestor (prescribing information). Wilmington, DE: AstraZeneca; 2007
42. Pravachol (prescribing information). Princeton, NJ: Bristol-Myers Squibb; 2007
43. Mevacor (prescribing information). Whitehouse Station, NJ: Merck & Co.; 2007
44. Zocor (prescribing information). Whitehouse Station, NJ: Merck & Co.; 2007
45. Lescol/Lescol XL (prescribing information). Dorval, Quebec: Novartis; 2006
46. Lipitor (prescribing information). New York, NY: Pfizer; 2007
47. Haney EM, Huffman LH, Bougatsos C, Freeman M, Steiner RD, Nelson HD. Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force. Pediatrics 2007;120:e189-e214
48. Kwiterovich PO, Jr., Barton BA, McMahon RP, Obarzanek E, Hunsberger S, Simons-Morton D, Kimm SY, Friedman LA, Lasser N, Robson A, Lauer R, Stevens V, Van Horn L, Gidding S, Snetselaar L, Hartmuller VW, Greenlick M, Franklin F, Jr. Effects of diet and sexual maturation on low-density lipoprotein cholesterol during puberty: the Dietary Intervention Study in Children (DISC). Circulation 1997;96:2526-2533
49. Clauss SB, Kwiterovich PO. Long-term safety and efficacy of low-fat diets in children and adolescents. Minerva Pediatr 2002;54:305-313
50. Kwiterovich PO, Jr., Chen SC, Virgil DG, Schweitzer A, Arnold DR, Kratz LE. Response of obligate heterozygotes for phytosterolemia to a low-fat diet and to a plant sterol ester dietary challenge. J Lipid Res 2003;44:1143-1155
51. Tricor (prescribing information). North Chicago, IL: Abbott Laboratories; 2004
52. WelChol (prescribing information). Parsipanny, NJ: Daiichi Sankyo, Inc.; 2006
53. Niaspan (prescribing information). Abbot Park, IL: Abbot Pharmaceuticals; 2007
54. Zetia (prescribing information). North Wales, PA: Merck/Schering-Plough Pharmaceuticals; 2007
55. Colestid (prescribing information). New York, NY: Pfizer; 2006
56. Lopid (prescribing information). New York, NY: Pfizer; 2003
57. Prevalite (prescribing information). Minneapolis, MN: Upsher-Smith Laboratories; 2006
58. Clauss SB, Holmes KW, Hopkins P, Stein E, Cho M, Tate A, Johnson-Levonas AO, Kwiterovich PO. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics 2005;116:682-688
59. de Jongh S, Ose L, Szamosi T, Gagne C, Lambert M, Scott R, Perron P, Dobbelaere D, Saborio M, Tuohy MB, Stepanavage M, Sapre A, Gumbiner B, Mercuri M, van Trotsenburg AS, Bakker HD, Kastelein JJ. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 2002;106:2231-2237
60. Dirisamer A, Hachemian N, Bucek RA, Wolf F, Reiter M, Widhalm K. The effect of low-dose simvastatin in children with familial hypercholesterolemia: a 1-year observation. Eur J Pediatr 2003;162:421-425
61. Knipscheer HC, Boelen CC, Kastelein JJ, van Diermen DE, Groenemeijer BE, van den Ende A, Buller HR, Bakker HD. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res 1996;39:867-871
62. Lambert M, Lupien PJ, Gagne C, Levy E, Blaichman S, Langlois S, Hayden M, Rose V, Clarke JT, Wolfe BM, Clarson C, Parsons H, Stephure DK, Potvin D, Lambert J. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. Pediatrics 1996;97:619-628
63. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr 2003;143:74-80
64. Stein EA, Illingworth DR, Kwiterovich PO Jr, Liacouras CA, Siimes MA, Jacobson MS, Brewster TG, Hopkins P, Davidson M, Graham K, Arensman F, Knopp RH, DuJovne C, Williams CL, Isaacsohn JL, Jacobsen CA, Laskarzewski PM, Ames S, Gormley GJ. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA 1999;281:137-144
65. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Buller HR, Sijbrands EJ, Kastelein JJ. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004;292:331-337
66. Liacouras CA, Coates PM, Gallagher PR, Cortner JA. Use of cholestyramine in the treatment of children with familial combined hyperlipidemia. J Pediatr 1993;122:477-482
67. Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr 1996;129:42-49
68. Naoumova RP, Thompson GR, Soutar AK. Current management of severe homozygous hypercholesterolemias. Curr Opin Lipidol 2004;15:413-422